Design and synthesis of tri-ring P 3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7520-7534

  Palmer, James T ^a   Bryant, Clifford ^a   Wang, Dan Xiong ^a   Davis, Dana E ^a   Setti, Eduardo L ^a   Rydzewski, Robert M ^a   Venkatraman, Shankar ^a   Tian, Zong Qiang ^a   Burrill, Leland C ^a   Mendonca, Rohan V ^a   Springman, Eric ^a   McCarter, John ^a   Chung, Tobee ^a   Cheung, Harry ^a   Janc, James W ^a   McGrath, Mary ^a   Somoza, John R ^a   Enriquez, Philip ^a   Yu, Z Walter ^a   Strickley, Robert M ^a   Liu, Liang ^a   Venuti, Michael C ^a   Percival, M David ^b   Falgueyret, Jean Pierre ^b   Prasit, Peppi ^b   Oballa, Renata ^b   Riendeau, Denis ^b   Young, Robert N ^b   Wesolowski, Gregg ^c   Rodan, Sevgi B ^c   Johnson, Colena ^c   Kimmel, Donald B ^c   Rodan, Gideon ^c   more..

^a CELERA   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACETONITRILE; AMINOCYCLOHEXANECARBOXYLATE; AMINONITRILE DERIVATIVE; BENZAMIDE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; CRA 013783; L 006235; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE DEFECT; CHIRALITY; COLLAGEN DEGRADATION; CONTROLLED STUDY; COW; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RHESUS MONKEY;

ADMINISTRATION, ORAL; ANIMALS; BENZAMIDES; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSINS; CATTLE; COLLAGEN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; KINETICS; MACACA MULATTA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NITRILES; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 28144433007     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058198r     Document Type: Article

References (31)

1. Peck, W. A.; Burckhardt, P.; Christiansen, C.; Fleisch, H. A.; Genant, H. K.; Gennari, C.; Martin, T. J.; Martini, L.; Morita, R.; Ogata, E.; Rapado, A.; Shulman, L. E.; Stern, P. H.; Young, R. T. T.; Barrett-Connor, E.; Brandi, M. L.; Chesnut, C. H.; Delmas, P. D.; Heaney, R. P.; Johnston, C. C.; Kanis, J. A.; Lindsay, R.; Meunier, P. J.; Papapoulos, S. E.; Reginster, J. Y.; Riggs, B. L.; Riis, B. J.; Seeman, E.; Wasnich, R. D. Consensus development conference: diagnosis prophylaxis and treatment of osteoporosis. Am. J. Med. 1993, 94, 646-650.
2. (a) Bromme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. Human Cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. J. Biol. Chem. 1996, 271, 2126-2132.
3. (b) Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.; Amegadzie, B. Y.; Hanning, C. R.; Jones, C.; Kurdyla, J. T.; McNulty, D. E.; Drake, F. H.; Gowen, M.; Levy, M. A. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 1996, 271, 12517-12524.
4. (c) Tezuka, K.; Tezuka, Y.; Maejima, A.; Sato, T.; Nemoto, K.; Kamioka, H.; Hakeda, Y.; Kumegawa, M. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 1994, 269, 1106-1109.
5. (a) Gelb, B. D.; Moissoglu, K.; Zhang, J.; Martignetti, J. A.; Bromme, D.; Desnick, R. J. Cathepsin K; isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis Gene. Biochem. Mol. Med. 1996, 59, 200-206.
6. (b) Johnson, M. R.; Polymeropoulos, M. H.; Vos, H. L.; Oritz de Luna, R. I.; Francomano, C. A. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 1996, 6, 1050-1055.
7. (c) Gelb, B. D.; Shi, G.-P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273, 1236-1238.
8. (a) Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Detlev, J. D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13453-13458.
9. (b) Gowen, M.; Lazner, F.; Dodds, R.; Kapadia, R.; Field, J.; Tavaria, M.; Bertoncello, I.; Drake, F.; Zavarselk, S.; Tellis, I.; Hertzog, P.; Debouck, C.; Kola, I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14, 1654-1663.
10. Votta, B. J.; Levy, M. A.; Badger, A.; Bradbeer, J.; Dodds, R. A.; James, I. E.; Thompson, S.; Bossard, M. J.; Carr, T.; Conner, J. R.; Tomaszek, T. A.; Szewczuk, L.; Drake, F. H.; Veber, D. F.; Gowen, M. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 1997, 12, 1396-1406.
11. (a) Marquis, R. W.; Ru, Y.; LoCastro, S. M.; Zeng, J.; Yamashita, D. S.; Oh, H.-J.; Erhard, K. F.; Davis, L. D.; Tomaszek, T. A.; Tew, D.; Salyers, K.; Proksch, J.; Ward, K.; Smith, B.; Levy, M.; Cummings, M. D.; Haltiwanger, R. C.; Trescher, G.; Wang, B.; Hemling, M. E.; Quinn, C. J.; Cheng, H.-Y.; Lin, F.; Smith, W. W.; Janson, C. A.; Zhao, B.; McQueney, M. S.; D'Alessio, K.; Lee, C.-P.; Marzulli, A.; Dodds, R. A.; Blake, S.; Hwang, S.-H.; James, I. E.; Gress, C. J.; Bradley, B. R.; Lark, M. W.; Gowen, M.; Veber, D. F. Azepanone-Based Inhibitors of Human and Rat Cathepsin K. J. Med. Chem. 2001, 44 (9), 1380-1395.
12. (b) Marquis, R. W.; Ru, Y.; Yamashita, D. S.; Oh, H.-J.; Yen, J.; Thompson, S. K.; Carr, T. J.; Levy, M. A.; Tomaszek, T. A.; Ijames, C. F.; Smith, W. W.; Zhao, B.; Janson, C. A.; Abdel-Meguid, S. S.; D'Alessio, K. J.; McQueney, M. S.; Veber, D. F. Potent dipeptidyl ketone inhibitors of the cysteine protease cathepsin K. Bioorg. Med. Chem. 1999, 7, 581-588.
13. (c) Marquis, R. W.; Yamashita, D. S.; Ru, Y.; LoCastro, S. M.; Oh, H.-J.; Erhard, K. F.; DesJarlais, R. L.; Head, M. S.; Smith, W. W.; Zhao, B.; Janson, C. A.; Abdel-Meguid, S. S.; Tomaszek, T. A.; Levy, M. A.; Veber, D. F. Conformationally constrained 1,3-diamino ketones: A series of potent and selective inhibitors of the cysteine protease cathepsin K. J. Med. Chem. 1998, 41, 3563-3567.
14. Mendonca, R. V.; Venkatraman, S.; Palmer, J. T. Novel route to the synthesis of peptides containing 2-amino-1′-hydroxymethyl ketones and their application as cathepsin K inhibitors. Bioorg. Med. Chem. Lett. 2002, 12 (20): 2887-2891.
15. McGrath, M. E.; Klaus, J. L.; Barnes, M. G.; Bromme, D. Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol. 1997, 4, 105-109.
16. (a) DesJarlais, R. L.; Yamashita, D. S.; Oh, H.-J.; Uzinskas, I. N.; Erhard, K. F.; Allen, A. C.; Haltwanger, R. C.; Zhao, B.; Smith, W. W.; Abdel-Meguid, S. S.; D'Allesio, K.; Janson, C. A.; McQueney, M. S.; Tomaszek, T. A.; Levy, M. A.; Veber, D. F. Use of X-ray cocrystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K. J. Am. Chem. Soc. 1998, 35, 9114-9115.
17. (b) Yamashita, D. S.; Smith, W. W.; Zhao, B.; Janson, C. A.; Tomaszek, T. A.; Bossard, M. J.; Levy, M. A.; Oh, H.-J.; Carr, T. J.; Thompson, S. K.; Ijames, C. F.; Carr, S. A.; McQueney, M.; D'Alessio, K. J.; Amegadzie, B. Y.; Hanning, C. R.; Abdel-Meguid, S.; DesJarlais, R. L.; Gleason, J. G.; Veber, D. F. Structure and Design of Potent and Selective Cathepsin K Inhibitors. J. Am. Chem. Soc. 1997, 119 (46), 11351-11352.
18. McGrath, M. E.; Sprengeler, P. A.; Hill, C. M.; Martichonok, V.; Cheung, H.; Somoza, J. R.; Palmer, J. T.; Janc, J. W., Peptide ketobenzoxazole inhibitors bound to cathepsin K. Biochemistry 2003, 42 (51), 15018-15028.
19. Greenspan, P. D.; Clark, K. L.; Tommasi, R. A.; Cowen, S. D.; McQuire, L. W.; Farley, D. L.; van Duzer, J. H.; Goldberg, R. L.; Zhou, H.; Du, Z.; Fitt, J. J.; Coppa, D. E.; Fang, Z.; Macchia, W.; Zhu, L.; Capparelli, M. P.; Goldstein, R.; Wigg, A. M.; Doughty, J. R.; Bohacek, R. S.; Knap, A. K. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. J. Med. Chem. 2001, 44, 4524-4534.
20. Ward, Y. D.; Thomas, D. S.; Frye, L. L.; Cywin, C. L.; Morwick, T.; Emmanuel, M. J.; Zindell, R.; McNeil, D.; Bekkali, Y.; Giradot, M.; Hrapchak, M.; DeTuri, M.; Crane, K.; White, D.; Pav, S.; Wang, Y.; Hao, M.-H.; Grygon, C. A.; Labadia, M. E.; Freeman, D. M.; Davidson, W.; Hopkins, J. L.; Brown, M. L.; Spero, D. M. Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors. J. Med. Chem. 2002, 45, 5471-5482.
21. (a) Robichaud, J.; Oballa, R.; Prasit, P.; Falgueyret, J.-P.; Percival, M. D.; Wesolowski, G.; Rodan, S. B.; Kimmel, D.; Johnson, C.; Bryant, C.; Venkatraman, S.; Setti, E.; Mendonca, R.; Palmer, J. T.; A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J. Med. Chem. 2003, 46 (17), 3709-3727.
22. (b) Bryant; C. M.; Palmer; J. T.; Rydzewski; R. M.; Setti; E. L.; Tian; Z-Q.; Venkatraman; S.; Wang; D-X. Compounds and compositions as protease inhibitors. U.S. Patent 6,593,327, July 15, 2003.
23. (c) Gabriel, T.; Pech, M.; Rodriguez Sarmiento, R. M. β-Amino acid nitrile derivatives useful for the treatment of diseases which are associated with cysteine proteases. World Patent 2001/96285, Chem. Abstr. 2001, 136, 53544.
24. (d) Missbach, M. Preparation of dipeptide cathepsin K inhibitors. World Patent 2001/58886, Chem. Abstr. 2001, 135, 180786.
25. (e) Altmann, E.; Betschart, C.; Gohda, K.; Horiuchi, M.; Lattmann, R.; Missbach, M.; Sakaki, J.; Takai, M.; Teno, N.; Cowen, S. D.; Greenspan, P. D.; McQuire, L. W.; Tommasi, R. A.; Van Duzer, J. H. Dipeptide nitriles. World Patent 9924460, Chem. Abstr. 1999, 130, 352553.
26. See, for example, Synthesis of Peptides and Peptidomimetics. In Houben-Weyl Methods of Organic Chemistry; Goodman, M., Felix, A., Moroder, L., and Toniolo, C., Eds.; Georg Thieme Verlag: Stuttgart, Germany, 2001; Volume E22A.
27. Giroux, A.; Han, Y.; Prasit, P. One Pot Biaryl Synthesis via in situ Boronate Formation. Tetrahedron Lett. 1997, 38, 3841-3844.
28. Falgueyret, J. P.; Oballa, R. M.; Okamoto, O.; Wesolowski, G.; Aubin, Y.; Rydzewski, R. M.; Prasit, P.; Riendeau, D.; Rodan, S. B.; Percival, M. D. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem. 2001, 44 (1), 94-104.
29. Collins, J. L.; Blanchard, S. G.; Boswell, G. E.; Charifson, P. S.; Cobb, J. E.; Henke, B. R.; Hull-Ryde, E. A.; Kazmierski, W. M.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J.; Lenhard, J. M.; Orband-Miller, L. A.; Gray-Nunez, Y.; Parks, D. J.; Plunkett, K. D.; Tong, W.-Q. N-(2-Benzoylphenyl)- L-tyrosine PPAR Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. J. Med. Chem. 1998, 41 (25), 5037-5054.
30. Kuzmic, P.; Sideris, S.; Cregar, L. M.; Elrod, K. C.; Rice, K. D.; Janc, J. W. High-throughput screening of enzyme inhibitors: Automatic determination of tight-binding inhibition constants. Anal. Biochem. 2000, 281, 62-67.
31. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185, 269-286.